# 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

> **NCT01549652** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 133 (actual)

## Conditions studied

- Opioid Withdrawal
- Physical Dependence

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Placebo
- **DRUG:** Morphine
- **DRUG:** Naloxone 0.4 mg/70 kg
- **DRUG:** Naloxone 0.8 mg/70 kg

## Key facts

- **NCT ID:** NCT01549652
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-04
- **Final completion:** 2016-10
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2019-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01549652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01549652, "5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01549652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*